Colorectal cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide, with treatment resistance and metastasis posing substantial clinical challenges. The current findings elucidate how LBX2, a transcriptional regulator previously implicated in developmental processes, is aberrantly expressed in colorectal tumors and significantly correlates with poor patient prognosis. The mechanistic insights presented reveal that LBX2 orchestrates a positive feedback loop by modulating key enzymes responsible for glycosylation and lactylation, two critical post-translational modifications that have emerged as regulators of cancer cell metabolism and gene expression.

The researchers employed a suite of molecular biology techniques, including chromatin immunoprecipitation sequencing and mass spectrometry-based proteomics, to map the direct LBX2 targets and profile the landscape of glycosylation and lactylation in colorectal cancer cells. Their results demonstrated elevated LBX2 expression enhances the transcription of glycosyltransferases and lactylation-related enzymes, which in turn modifies LBX2 and associated transcription complexes. These modifications strengthen LBX2’s DNA binding affinity and transcriptional activity, creating a potent feed-forward loop that drives oncogenic gene expression programs.

Functional assays revealed that disrupting either glycosylation or lactylation pathways markedly reduces LBX2-driven cellular proliferation and invasiveness, underscoring the therapeutic potential of targeting these modifications. Notably, the study provides compelling evidence that lactylation, a relatively newly discovered post-translational modification derived from lactate metabolism, plays a central role in colorectal tumor progression by stabilizing key proteins and enhancing gene expression under hypoxic and glycolytic tumor microenvironments.

This biochemically intricate feedback system underscores the multifaceted role of metabolic reprogramming in colorectal cancer pathogenesis. By linking LBX2 activity to dynamic modifications like glycosylation and lactylation, the study opens new avenues for understanding how cancer cells exploit epigenetic and metabolic plasticity to sustain malignant growth and evade conventional therapies.

Beyond the immediate implications for colorectal cancer, these findings contribute to a broader conceptual framework that positions post-translational modifications as critical nodes in oncogenic signaling networks. The convergence of glycosylation and lactylation on LBX2 suggests a coordinated regulatory axis that balances nutrient availability, cellular metabolism, and transcriptional control—a paradigm that may be relevant to other aggressive cancers.

From a translational perspective, targeting enzymes involved in glycosylation and lactylation, or directly interfering with LBX2 expression and function, could represent a novel therapeutic strategy. Given the positive feedback nature of this circuit, pharmacological disruption has the potential to induce a collapse of the oncogenic network, thereby enhancing treatment efficacy and possibly overcoming resistance to current chemotherapeutic agents.

The methodological rigor and interdisciplinary approach of this investigation also underscore the importance of integrating genomic, proteomic, and metabolic data to unravel cancer complexity. Leveraging advanced imaging and biochemical assays, the researchers could systematically dissect the interaction between LBX2 modifications and chromatin dynamics, thus providing an unprecedented level of detail on the spatial and temporal regulation of oncogenic transcription factors.

Moreover, the study highlights the significance of tumor microenvironmental factors, such as hypoxia-induced lactate accumulation, in modulating cancer progression through post-translational modifications. This insight might prompt further exploration into metabolic interventions aimed at altering the tumor milieu to disrupt pathological feedback loops like the one driving LBX2 activity.

In conclusion, the identification of LBX2 as a master regulator of colorectal cancer progression via a glycosylation and lactylation-mediated positive feedback loop represents a milestone in cancer research. This discovery not only deepens our mechanistic understanding of tumor biology but also sets the stage for innovative therapeutic interventions targeting the intricate molecular crosstalk between metabolism and transcriptional control. As research advances, exploiting this vulnerability could significantly improve outcomes for patients suffering from colorectal cancer, reinforcing the critical intersection of metabolism, epigenetics, and oncogenesis.

Subject of Research:
Article Title:
Article References: Jiang, Y., Wang, L., Chen, L. et al. LBX2 promotes colorectal cancer progression via the glycosylation and lactylation positive feedback. Cell Death Discov. 11, 556 (2025). https://doi.org/10.1038/s41420-025-02888-w
Image Credits: AI Generated
DOI: 12 December 2025
Keywords:

The team, led by esteemed researchers Yan, Sun, and Shi, elaborated on the significance of glycolysis in cancer biology. This metabolic process allows cancer cells to generate energy rapidly, a phenomenon known as the Warburg effect. By diverting glucose into fermentation products even in the presence of oxygen, cancer cells can sustain their high proliferation rates. The inhibition of PKM2 localization into the nucleus by Triclabendazole represents a critical juncture in targeting this metabolic switch. The nuclear presence of PKM2 has been shown to facilitate the synthesis of nucleotides and lipids, both of which are essential for the growth of cancer cells, highlighting the importance of this newfound regulatory pathway.

At the molecular level, the research delved into the interplay between PKM2 and Histone Deacetylase 6 (HDAC6). The study posited that Triclabendazole enhances the deacetylation of PKM2 through HDAC6. This process not only hinders the nuclear translocation of PKM2 but also contributes to the overall dysregulation of cancer cell metabolism. The hyperacetylation status of PKM2, when localized in the nucleus, is pivotal for its function in promoting glycolysis. Hence, the enhancement of HDAC6-mediated deacetylation by Triclabendazole could represent a potent strategy for metabolic reprogramming in lung cancer cells.

Moreover, the findings underscore the potential for repurposing existing drugs for oncology applications. Triclabendazole, with its established safety profile, presents a low-risk option for clinical trials aimed at repositioning it as an anticancer therapeutic. The implications of this research could resonate across various cancer types, given the universal nature of metabolic reprogramming in malignancies. By elucidating a novel mechanism of action, the study paves the way for future investigations into how HDAC6 modulation can serve as a target for cancer therapies.

The research utilized a combination of in vitro and in vivo experimental models to validate their hypotheses. Cell culture studies demonstrated that Triclabendazole effectively reduced the levels of PKM2 in the nucleus of lung cancer cell lines. Furthermore, animal models treated with the drug exhibited a significant decrease in tumor growth and enhanced survival rates compared to controls. These compelling results establish a strong foundation for further exploration into the clinical applicability of Triclabendazole in lung cancer therapy.

In the broader context of cancer treatment, the study also touches on the critical challenges faced in overcoming drug resistance. Many cancer therapies are rendered ineffective as tumors evolve mechanisms to evade treatment. By targeting metabolic pathways rather than single oncogenic drivers, Triclabendazole could provide a multifaceted approach to circumventing resistance, particularly when used in combination with existing therapies that target specific genetic aberrations.

The current research contributes essential knowledge to the emerging field of metabolic oncology. The understanding that metabolic shifts can dictate tumor behavior is reshaping how researchers view cancer treatment modalities. Rather than solely focusing on genetic mutations, increasingly, the spotlight is on the metabolic adaptations that fuel cancer progression. Triclabendazole’s dual role in inhibiting PKM2 activity and promoting HDAC6 activity exemplifies the innovative approaches scientists are exploring to strike at the roots of cancer metabolism.

Moreover, as the scientific community seeks to better understand the role of the tumor microenvironment in modulating metabolic pathways, the insights gained from this research could influence future therapeutic strategies. Targeting the metabolic landscape of tumors is becoming an attractive avenue for intervention, particularly in hypoxic microenvironments where traditional therapies may falter. Triclabendazole’s ability to disrupt glycolytic flux positions it as a promising candidate for integrative cancer treatment protocols.

As lung cancer remains one of the leading causes of cancer-related mortality worldwide, the significance of these findings cannot be overstated. The potential to repurpose a well-established drug like Triclabendazole underscores the urgency and necessity for ongoing research in this domain. With continued investigation and clinical validation, this research could lead to significant breakthroughs in how we approach lung cancer treatment, ushering in a new era of therapies that leverage metabolic vulnerabilities.

The forthcoming clinical trials will be pivotal in determining the efficacy and safety of Triclabendazole in lung cancer patients. By gathering more data on its therapeutic window and the mechanisms of action, researchers aim to refine treatment protocols. Ultimately, the goal is to establish a compelling case for integrating Triclabendazole into standard oncological practice, fundamentally changing the trajectory of treatment for lung cancer patients.

As research progresses, the emphasis will also be on understanding the broader implications of Triclabendazole’s action across different cancer types. The metabolic underpinnings of cancer are complex and varied, suggesting that drugs impacting metabolism could have far-reaching effects. The quest for effective cancer treatments that can complement or replace existing interventions is a vital area of scientific inquiry.

In conclusion, the study of Triclabendazole’s role in inhibiting PKM2 nuclear localization and glycolysis through the enhancement of HDAC6-mediated deacetylation unveils a trove of possibilities for lung cancer therapy. By highlighting a drug repurposing strategy that exploits cancer cell metabolism, the research not only sheds light on a critical aspect of tumor biology but also offers hope for improved therapeutic outcomes in a disease notorious for its lethality. Future investigations inspired by these findings may spearhead a paradigm shift in how metabolic processes can be harnessed to combat cancer effectively.

Subject of Research: Lung cancer and metabolic regulation by Triclabendazole.

Article Title: Triclabendazole inhibits PKM2 nuclear localization and glycolysis by enhancing HDAC6-mediated deacetylation in lung cancer.

Article References:

Yan, L., Sun, Y., Shi, Ss. et al. Triclabendazole inhibits PKM2 nuclear localization and glycolysis by enhancing HDAC6-mediated deacetylation in lung cancer.
J Transl Med 23, 1001 (2025). https://doi.org/10.1186/s12967-025-06905-5

Image Credits: AI Generated

DOI: 10.1186/s12967-025-06905-5

Keywords: Triclabendazole, lung cancer, PKM2, glycolysis, HDAC6, drug repurposing, metabolic regulation.